Researchers Reveal: Quitting Alcohol And Cleaning Up Your Diet Won't Move Your Liver Numbers...See Why (And What Actually Does)

In my work reviewing liver metabolism research, there is a concerning pattern that shows up more consistently than any other:

A patient is told their liver enzymes are elevated. They quit drinking entirely. They start the Mediterranean diet. They lose some weight. They start doing 10,000 steps a day. They start taking a generic "milk thistle" supplement. And 6 months later their ALT has barely moved, or even gotten worse.

This is NOT a failure of your own routine or discipline. It is the failure of modern medicine's treatment of NAFLD progression, and it appears across the published literature with a concrning level of consistency.

The standard protocol, cut the alcohol, clean up the diet, lose 10% of body weight, is not inherently wrong. But for a meaningful percentage of patients, it is vastly incomplete. What's missing is the part that determines whether the liver actually clears the fat trapped inside it.

What I'm going to walk you through is the mechanism most patients never have explained to them, and the clinical trial that quantified it: 107 patients with confirmed NAFLD, followed for 120 days, with approximately 50% less liver fat visible on ultrasound at the end of the study window. Not a survey. Not a self-report. Ultrasound imaging.

Does any of this sound familiar?

• You quit drinking 3, 6, 12 months ago, and your ALT still won't come down
• 6 months on the Mediterranean diet with bloodwork that barely budged
• Bouncing between Mediterranean, keto, and intermittent fasting because no diet moves the needle
• Hundreds of dollars wasted on Milk Thistle capsules that haven't touched your enzymes in months
• A "liver stack" on your windowsill: TUDCA, NAC, dandelion, artichoke, turmeric, whatever the forums swore by that week
• A doctor who said "give it more time, we'll retest in 6 months," and then 6 months later said the same thing

If this sounds familiar, you are not failing the protocol, and you are not alone. The protocol is failing a meaningful subset of the patients it's prescribed to. And the reason has nothing to do with willpower, sobriety, or how many miles you walked this week.

It has to do with a specific cellular process inside your liver, one that, in most NAFLD patients, has gone dormant and stays dormant even after the drinking stops.

Why Quitting Alcohol And Cleaning Up The Diet Doesn't Restart The Liver's Clearance System

Here's what most general practitioners, and even many hepatologists, don't explain to patients during the initial diagnosis conversation:

"Just stop drinking."

Alcohol cessation is the single most important intervention for a patient whose steatosis has an alcoholic component. It stops the ongoing metabolic damage caused by acetaldehyde exposure and reduces the oxidative load on hepatocytes. Every clinician who tells you to quit is giving you correct advice.

But what most clinicians don't say is this: quitting stops the input. It does not, by itself, clear the fat already deposited inside the cell. A patient who quits after years of drinking is still walking around with a liver full of stored triglycerides. Cessation removes the source. It does not activate the drain.

"Just lose 10% of your body weight."

The 10% weight loss target comes from real clinical data showing meaningful reductions in liver fat at that threshold. But the data also show something most patients never hear: a substantial portion of NAFLD patients on lifestyle-only management plateau at F1 to F2 fibrosis and progress anyway. Weight loss reduces the rate of new fat accumulation. It does not, by itself, restart the cellular process that clears the fat already deposited inside hepatocytes.

"Try the Mediterranean diet. Then keto. Then carnivore."

The Mediterranean diet has the strongest evidence base of any dietary pattern for NAFLD. But strength of evidence is not the same as clinical outcome for a given patient. Many patients report the same trajectory: six weeks on Mediterranean with no movement on ALT, switch to keto because a forum said carbs were the real culprit, then a follow-up panel shows ALT climbing on the higher-fat pattern, then a return to Mediterranean, then intermittent fasting layered on top. The diet-war shuffle changes what's coming in. It does not restart the process that clears what's already there.

"Take milk thistle."

Silymarin, the active compound in milk thistle, is a real molecule with real biological activity. It stabilizes hepatocyte cell membranes and provides antioxidant support. It does not initiate lipid clearance. It protects the cell. It does not empty it. A large randomized trial at high dose over roughly a year showed no meaningful change in ALT or AST. For a patient with established steatosis, silymarin addresses the wrong stage of the disease.

"Add TUDCA. Add NAC. Add dandelion. Add artichoke."

The bolt-on supplement stack is one of the most common patterns I see in patient histories. Six bottles on the windowsill by month three. The instinct is understandable: if one supplement isn't moving the numbers, add another. But none of the standard "liver support" compounds target the upstream mechanism. They protect. They buffer. They scavenge free radicals. None of them switch the cellular clearance system back on. And on top of that, a compromised liver processes capsules poorly, meaning even the compounds that might have helped never arrive at the tissue in meaningful concentrations.

None of the interventions above have produced anything close to the imaging outcome the Calabria team documented in their 107-patient cohort over 120 days. The gap between standard recommendations, alcohol cessation, dietary overhaul, protective supplements, and what's actually been measured under controlled conditions is wider than most patients are ever told.

Discover the cellular mechanism most hepatologists never explain to NAFLD patients →

The Real Reason Your Liver Enzymes Won't Come Down After You Quit

Inside every hepatocyte, every cell in your liver, there is a self-cleaning process called lipophagy.

In a healthy liver, lipophagy runs automatically. Fat droplets accumulate inside the cell during normal metabolism, and lipophagy breaks them down and clears them out. The system is supposed to be continuous and self-regulating. You shouldn't have to think about it.

In NAFLD, this system stalls. And in patients with a history of alcohol use, the stall is often more pronounced. Years of ethanol exposure suppress AMPK activity, the cell's master energy sensor, at the transcriptional level. When the drinking stops, the damage stops. But the AMPK suppression, and the resulting lipophagy shutdown, does not automatically reset. The liver stays in a fat-storage-dominant state even after the drinking is behind you.

The mechanism is well documented. As liver fat accumulates beyond a certain threshold, and as chronic ethanol exposure compounds the effect, AMPK activity drops. AMPK is what tells the cell when to store fat and when to burn it. When AMPK activity drops, lipophagy goes dormant. And once lipophagy is dormant, the fat already inside the cell stops being cleared. New fat, from any source, deposits faster than the system can remove it. The cell becomes lipid-loaded. On ultrasound, your liver appears "bright." On bloodwork, your ALT and AST climb.

Here is the part most patients are never told:

Your liver isn't struggling because of what you drank last year, or what you ate yesterday. It's struggling because the cellular system designed to clear that fat has gone dormant. Neither alcohol cessation nor dietary change, on their own, switches it back on.

This is the self-reinforcing loop at the center of NAFLD progression. And it is why a patient who quit drinking two years ago and has been on a strict Mediterranean diet ever since can still see fibrosis progression on their follow-up elastography. The interventions are slowing the rate of new fat accumulation. Nothing in the protocol is reactivating AMPK or restarting lipophagy.

The relevance of the Catanzaro trial is precisely this: across 120 days, in 107 patients, lipophagy markers were measurably elevated, AMPK activity was restored, and liver fat on ultrasound dropped by approximately half. The mechanism wasn't theorized. It was switched back on, and the imaging confirmed it.

Cessation stops the input. Diet slows the accumulation. Neither restarts the drain.

What 107 Patients Showed In 120 Days

Along the southern coast of Italy, in the Calabria region, grows a citrus fruit called bergamot, the same fruit that flavors Earl Grey tea. For decades, researchers at the University of Catanzaro have studied bergamot for its metabolic effects. In 2015, a team led by Dr. Maddalena Parafati published a study that shifted the conversation around NAFLD nutraceutical research.

The trial enrolled 107 patients with confirmed non-alcoholic fatty liver disease and metabolic syndrome. The observation window was 120 days. Patients received a standardized bergamot polyphenolic fraction, the concentrated extract isolated from bergamot peel, rich in compounds called flavonoids and polyphenols.

The numbers that mattered, measured on ultrasound imaging and standard liver panel:

• Approximately 50% reduction in liver fat content visible on hepatic ultrasound at day 120
• ALT normalized from a study mean of 67 down to 31 over the same 120-day window
• Significant improvement in steatosis scores across the full 107-patient cohort
• Elevation of LC3 and Beclin 1, the molecular markers of active lipophagy, confirming the mechanism

It is worth stopping on the first line. Half the liver fat. Visible on imaging. Across 107 patients. In 120 days. For a condition whose standard recommendation is "give it twelve to twenty-four more months and we'll re-image," the imaging delta over four months is, in clinical terms, not a small finding.

The clinical implication was direct: bergamot polyphenols reactivated AMPK, which restarted lipophagy, which cleared stored hepatic fat. The pathway that the abstinence alone could not switch on, and the diet alone could not switch on, the extract did.

This is not the same evidence base as a typical liver supplement. Most ingredients marketed for "liver support," milk thistle, dandelion root, turmeric, TUDCA, have either no human clinical data, or human data showing protective effects without measurable improvement in liver fat on imaging. Bergamot polyphenolic fraction is, to date, the only widely available nutraceutical ingredient with published clinical trial data on a 107-patient cohort showing approximately 50% reduction in hepatic fat on ultrasound at 120 days.

Why The Delivery Form Matters As Much As The Compound

This is the part of the conversation that most supplement labels obscure.

When you swallow a capsule, the active compounds inside it must first survive your stomach acid, then be absorbed across the intestinal wall, and then travel via the portal vein directly to your liver. This is called hepatic first-pass metabolism. The liver processes, and degrades, a substantial portion of the active compound before any of it reaches systemic circulation.

For a healthy liver, this is not a major concern. For a compromised liver, it is the whole problem.

A liver already struggling to process stored triglycerides, oxidized lipids, and the residual metabolic load from years of alcohol exposure is the same organ being asked to break down a capsule, its binders, its fillers, and its active compounds, all before any of it can reach the bloodstream. A meaningful fraction of the bergamot polyphenols in a capsule never make it past the first pass.

This is one of the most overlooked reasons the milk thistle and TUDCA capsules on a patient's windowsill produce so little movement on bloodwork. The compounds themselves may have real biological activity. The delivery form ensures the tissue barely sees them.

Sublingual delivery bypasses this entirely. Liquid drops held under the tongue absorb directly through the sublingual mucosa into the bloodstream, circumventing the digestive tract and the portal vein. The active compounds reach systemic circulation intact, at a fraction of the dose a capsule would require to deliver the same bioavailable amount.

For patients with established NAFLD, especially those with a history of alcohol use, the choice of delivery form is not a marketing detail. It is the difference between giving the liver a tool and giving it more work.

See how sublingual bergamot delivery compares to capsule absorption →

Introducing Pura Bergamot Liver Cleanse Formula

Pura's Bergamot Liver Cleanse Formula was built around a single clinical question: how do you deliver the same bergamot polyphenolic fraction studied in the 107-patient Catanzaro cohort, in a form a compromised liver can actually use, alongside the supporting compounds needed to protect hepatocytes while AMPK reactivation does its work?

What makes the formula different from a generic capsule:

• Built around the bergamot polyphenolic fraction studied in the 107-patient, 120-day Catanzaro cohort
• Sublingual liquid delivery, bypasses hepatic first-pass metabolism
• Targets the upstream mechanism: AMPK reactivation and lipophagy restoration
• Supporting compounds selected for hepatocyte protection during the clearance window

The Science-Backed Formula

See how these ingredients work together to restart hepatic lipid clearance →

Real People. Real Liver Numbers.

Try Pura Risk-Free Today

If you have an NAFLD diagnosis, an elevated ALT, or a recent ultrasound showing hepatic steatosis, and you have already quit drinking, cleaned up your diet, and cycled through the standard supplement stack without seeing the bloodwork move, Pura Bergamot Liver Cleanse Formula gives you a tool that addresses the upstream mechanism: stalled lipophagy, dormant AMPK, the stored fat that neither abstinence nor diet alone can clear. The same compound class. The same target window. 107 patients. 120 days. Approximately 50% less liver fat on ultrasound.

Every order is backed by a 90-day money-back guarantee. If your follow-up labs don't show measurable improvement, return the bottle, even if it's empty, for a full refund. The brand is aligning its margin with your bloodwork. That is the only honest test of a liver support product.